Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuroprotective effects of trans-anethole on AlCl₃-induced memory impairment: targeting AChE, oxidative stress, and NLRP3 inflammasome: a promising approach for neurodegeneration prevention.

Metabolic brain disease·2026
Same author

Targeting Shared Mechanisms in Atherosclerosis and Alzheimer's Disease.

Current Alzheimer research·2026
Same author

Formononetin attenuates neuroinflammation and confers neuroprotection in a pentylenetetrazol-induced kindling model of epilepsy in mice.

Inflammopharmacology·2026
Same author

Steroidal alkaloids: Exploring new therapeutic frontiers in cardiovascular diseases.

Steroids·2026
Same author

A critical appraisal of drug transport across the blood-brain barrier: Evaluation using new-age microfluidic technique.

Brain research bulletin·2025
Same author

Multi-Target Approach for Drug-Resistant Epilepsy: An In Silico Exploration of Promising Phytochemicals.

Chemistry & biodiversity·2025

Related Experiment Video

Updated: Jun 13, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Rotenone in Drug-Resistant Epilepsy Models: Powerful Tool or Problematic Paradigm?

Nidhi Khedpande1, Kalyani Barve2

  • 1Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University, Mumbai, 400056, India.

Neurochemical Research
|June 12, 2026
PubMed
Summary

The rotenone adjuvant PTZ-kindling model effectively mimics drug-resistant epilepsy (DRE) features like pharmacoresistance and neuroinflammation. This model shows promise for testing new therapies targeting mitochondrial dysfunction and inflammation in DRE.

Keywords:
Drug-resistant epilepsyMitochondrial dysfunctionNeuroinflammationPharmacoresistanceRotenone adjuvant kindling

More Related Videos

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
09:22

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning

Published on: June 22, 2015

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Experiment Videos

Last Updated: Jun 13, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
09:22

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning

Published on: June 22, 2015

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Drug-resistant epilepsy (DRE) presents significant treatment challenges.
  • Existing models often lack comprehensive clinical feature replication.
  • Mitochondrial dysfunction and neuroinflammation are implicated in DRE pathogenesis.

Purpose of the Study:

  • To evaluate the rotenone adjuvant pentylenetetrazol (PTZ)-kindling paradigm as a model for DRE.
  • To assess its construct, face, and predictive validity compared to traditional models.
  • To determine its suitability for testing novel mechanism-based therapies.

Main Methods:

  • Combined rotenone (mitochondrial complex I inhibitor) with PTZ or corneal kindling.
  • Administered repeated subconvulsive doses of PTZ to induce epileptogenesis.
  • Assessed seizure susceptibility, neuroinflammation, oxidative stress, and drug penetration.

Main Results:

  • The model replicated key DRE features: pharmacoresistance, neuroinflammation, and oxidative stress.
  • Rotenone potentiated PTZ sensitivity, affecting blood-brain barrier integrity and transporter expression.
  • The paradigm showed construct, face, and predictive validity, including comorbidities and spontaneous seizures.

Conclusions:

  • The rotenone adjuvant PTZ-kindling model is a promising translational platform for DRE research.
  • It offers improved clinical relevance for evaluating therapies targeting mitochondrial dysfunction, GABAergic imbalance, and inflammation.
  • Limitations include systemic toxicity, mortality, and inter-animal variability that require further investigation.